Clinical trials: SARS
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
- Trial name
- NCT05375838
- Testing
- mRNA-1073, mRNA-1010, mRNA-1273
- Where
- 14 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19 by SARS-CoV-2 Infection
Role of Inflammasomes in COVID-19 Disease
As of March 25, 2020, 414,179 cases and 18,440 deaths secondary to Coronavirus 2019 disease (COVID-19) have been reported worldwide.
- Trial name
- CoVInnate (NCT04385017)
- Testing
- COVID-19 patients
- Where
- 2 sites in France
- Volunteers
- 99 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
COVID-19
Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19
This study is a randomized, double-blinded, and placebo-controlled phase Ia/IIa clinical trial of the Inactivated SARS-CoV-2 Vaccine to evaluate the safety and immunogenicity of the vaccine in healthy people aged 18~59 Years.
- Trial name
- NCT04412538
- Testing
- Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule, Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule, Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
- Where
- China
- Volunteers
- 942 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
COVID-19 Pandemic, COVID-19 Vaccines
UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)
The goal of this open-label clinical trial is to evaluate the safety and immunogenicity of INAVAC (Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated)) Vaccine as Homologue Booster in Adult Subjects in Indonesia.
- Conditions
- COVID-19 Pandemic, COVID-19 Vaccines, COVID-19 Virus Disease
- Trial name
- NCT06259578
- Testing
- INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg
- Where
- Indonesia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital
Heathly Subjects Susceptible to SARS-CoV-2 Infection
Microbiome-Based Risk Prediction of SARS-CoV-2 in Children and Families (PREDICOL)
The goal of this observational cohort study is to evaluate the association between gut microbiota composition, dietary patterns, lifestyle-related factors, and neurodevelopmental outcomes, as well as susceptibility to SARS-CoV-2…
- Trial name
- PREDICOL (NCT07717008)
- Where
- Spain
- Volunteers
- 932 people, healthy volunteers welcome
- Sponsor
- Spanish National Research Council
COVID-19
Study for Efficacy and Safety Assessment of the Drug RADAMIN®VIRO for COVID-19 Postexposure Prophylaxis
This is Double-Blind, Placebo-Controlled Multicentre Clinical Phase III Study conducted in 10 medical facilities. The objective of the study is to evaluate efficacy and safety of the drug Drug RADAMIN®VIRO, Lyophilisate for…
- Trial name
- NCT05722691
- Testing
- Double-Stranded RNA sodium salt
- Where
- 10 sites in Russia
- Volunteers
- 800 people
- Sponsor
- Promomed, LLC
End-stage Renal Disease, SARS-CoV-2 Acute Respiratory Disease
SARS-COV-2 Screening in Dialysis Facilities
Patients receiving dialysis are one of the highest risk groups for serious illness with SARS-CoV-2 infection. In addition to the inherent risks of travel to and dialysis within indoor facilities, patients receiving dialysis are…
- Conditions
- End-stage Renal Disease, SARS-CoV-2 Acute Respiratory Disease, Dialysis; Complications
- Trial name
- NCT05225298
- Testing
- Offering SARS-CoV-2 test
- Where
- United States
- Volunteers
- 2,389 people
- Sponsor
- Stanford University
SARS-CoV2 Infection
Nigella 5 in the Treatment of SARS COV2 (COVID-19)
The world is currently facing a crisis because of this potentially fatal situation of the COVID-19 epidemic without proven efficacy for any drug treatment, while the vaccination is not yet.
- Trial name
- Nigelle5 (NCT04914767)
- Testing
- Nigella
- Where
- 2 sites in Tunisia
- Volunteers
- 500 people
- Sponsor
- Hôpital Universitaire Sahloul
COVID19, Coronavirus Infection
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
This is a prospective study, using plasma to help fight off infections of those suffering from COVID-19 in accordance with collection guidelines for plasma and FDA IND requirements.
- Conditions
- COVID19, Coronavirus Infection, Coronavirus, Virus Diseases
- Trial name
- NCT04376034
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- West Virginia University
SARS-CoV Infection
Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
The purpose of this research is to identify whether or not Angiotensin Receptor Blockers (ARB) can halt the progression to respiratory failure requiring transfer into the intensive care unit (ICU), as well as halt mechanical…
- Trial name
- NCT04340557
- Testing
- Losartan
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sharp HealthCare
SARS-CoV 2, COVID-19
Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19
Prospective study for clinical performance evaluation of COVID-19 diagnostic tests: detection of anti-SARS-CoV-2 antibodies by RDTs or ELISA (manual or automated), rapid diagnostic tests based on antigen detection, molecular or…
- Trial name
- ERap-COV (NCT04405492)
- Testing
- Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling., Capillary and salivary sampling
- Volunteers
- 1,210 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Breath Samples Collection Clinical Trial, for Development of the TERA BioStation T101, Intended for CoV-19 Exhalation Products Detection.
The Sponsor has developed a rapid screening tool intended to determine if the subject tested has COVID-19.
- Trial name
- NCT05162495
- Testing
- BioStation T101 and TeraTube
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tera Group
SARS-CoV2 Infection, Rare Diseases
Identification of Factors Associated With the Occurrence of Severe Forms of COVID-19 Infection in Patients With Inflammatory Rheumatism or Autoimmune Diseases
Factors associated with severe forms of COVID-19 infection in patients with inflammatory rheumatic diseases (IRD) or Autoimmune Diseases (AID) are unknown.
- Conditions
- SARS-CoV2 Infection, Rare Diseases, Chronic Inflammatory Rheumatism, Autoimmune Diseases
- Trial name
- CovAID (NCT05026892)
- Testing
- no intervention
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Covid19
Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection
Evelo will investigate the safety and efficacy of EDP1815 in the treatment of patients hospitalized with SARS-CoV-2 Infection
- Trial name
- NCT04488575
- Testing
- EDP1815
- Where
- 4 sites in United States, Turkey (Türkiye)
- Volunteers
- 16 people
- Sponsor
- Evelo Biosciences, Inc.
Intensive Care Unit, SARS-Cov-2
COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study
Infection with the SARS-CoV-2 coronavirus (COVID-19) has recently been identified as a pandemic due to the speed and global scale of its transmission.
- Trial name
- RICO (NCT04392401)
- Testing
- Collection of blood samples in order to create a biocollection
- Where
- 8 sites in France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Covid19
Low Dose Lung Radiotherapy to Treat COVID-19 Pneumonia
The purpose of this study is to document the feasibility and tolerability of low dose thoracic radiotherapy in patients with WHO level 5 COVID 19 infections.
- Trial name
- NCT04572412
- Testing
- Low dose Radiotherapy
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- Lancashire Teaching Hospitals NHS Foundation Trust
SARS-CoV-2, Coronavirus
Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary
The additional effect of personalized health education compared to general education following the internationally accepted principles will be evaluated in the prevention of the serious course of the novel coronavirus infection.
- Conditions
- SARS-CoV-2, Coronavirus, COVID-19, 2019-nCoV
- Trial name
- PROACTIVE-19 (NCT04321928)
- Testing
- Personalized health education, General health education
- Where
- Hungary
- Volunteers
- 449 people, healthy volunteers welcome
- Sponsor
- University of Pecs
COVID-19
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19.
- Trial name
- NCT04880109
- Testing
- APX-115
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Aptabio Therapeutics, Inc.
Severe COVID-19
COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
Multicenter observational retrospective cohort study aiming at comparing the incidence of ventilator-associated lower respiratory tract infections between COVID-19 patients from the first and the second wave of the pandemic.
- Trial name
- CoVAPid2 (NCT05256511)
- Where
- France
- Sponsor
- University Hospital, Lille
Fever
Timing of Surgery in Pediatric Patients Following Fever Recovery: a Prospective Cohort Study
Objectives: The timing of fever recovery may affect the risk of intra-operative hypoxemia in children undergoing elective surgery after SARS-CoV-2 infection.
- Trial name
- NCT06568809
- Testing
- Time interval between recovery of body temperature and operation
- Where
- China
- Volunteers
- 3,053 people
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University